Abstract
Organ-specific differences in epidermal growth factor receptor (EGFR) mutational spectra and frequencies were found in lung cancer and sporadic and BRCA1/2-related breast cancers. Additionally, we found a high frequency of EGFR mutations in the tumour stroma of these invasive breast carcinomas. Those organ-specific mutational spectra and potential targets in the cancer-associated stroma might influence the efficacy of TKI therapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology
-
Carcinoma / genetics*
-
Carcinoma / pathology
-
DNA Mutational Analysis
-
Enzyme Inhibitors / pharmacology*
-
ErbB Receptors / genetics*
-
Genes, BRCA1
-
Genes, BRCA2
-
Humans
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / pathology
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Stromal Cells
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
ErbB Receptors
-
Protein-Tyrosine Kinases